(Q34394974)

1 August 2017

1 reference

title

Pathobiology of pulmonary hypertension. The role of platelets and thrombosis (English)

1 reference

1 August 2017

0 references

4

Parent F

1 reference

1 August 2017

8

Simonneau G

1 reference

1 August 2017

Herve P

1

1 reference

1 August 2017

Humbert M

2

1 reference

1 August 2017

Sitbon O

3

1 reference

1 August 2017

Nunes H

5

1 reference

1 August 2017

Legal C

6

1 reference

1 August 2017

Garcia G

7

1 reference

1 August 2017

1 September 2001

1 reference

Clinics in Chest Medicine

1 August 2017

1 reference

1 August 2017

22

1 reference

1 August 2017

3

1 reference

1 August 2017

451-458

1 reference

Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

Pulmonary hypertension and right heart failure in patients with beta-thalassemia intermedia.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

Evaluation of patients with suspected chronic thromboembolic pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

Plasma levels of thrombomodulin in pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

The role of thrombosis in severe pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

Characterization of von Willebrand factor in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

Pulmonary hypertension and cor pulmonale in the sickle hemoglobinopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

Obesity drugs and the heart

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

Angioscopic video-assisted pulmonary endarterectomy for post-embolic pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

Imbalance between Platelet Vascular Endothelial Growth Factor and Platelet-derived Growth Factor in Pulmonary Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

Primary pulmonary hypertension: natural history and the importance of thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: role of serotonin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

Increased plasma serotonin in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

Plasma coagulation profiles in patients with severe primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

Pulmonary Hypertension after Splenectomy?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

Circulating platelet aggregates indicative of in vivo platelet activation in pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

Heterogeneity of pathologic lesions in familial primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

Phentermine and other monoamine-oxidase inhibitors may increase plasma serotonin when given with fenfluramines

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

Primary pulmonary hypertension, tissue plasminogen activator antibodies, and HLA-DQ7

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

Chronic major-vessel thromboembolic pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

Do patients with primary pulmonary hypertension develop extensive central thrombi?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

Endogenous fibrinolytic system in chronic large-vessel thromboembolic pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

Pulmonary Hypertension Associated with Long-standing Thrombocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

Microangiopathic Hemolytic Anemia and Thrombocytopenia in Primary Pulmonary Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

Pulmonary hypertension in sickle cell disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

Microangiopathic hemolytic anemia and thrombocytopenia in a child with atrial septal defect and pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

Pulmonary hypertension and sickle hemoglobinopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

Improvement of von Willebrand Factor Proteolysis After Prostacyclin Infusion in Severe Pulmonary Arterial Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

Pathology of pulmonary thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

Thrombotic risk factors in pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

Absence of hyperhomocysteinemia in ten patients with primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970283-5

7 January 2021

10.1016/S0272-5231(05)70283-5

Identifiers

DOI

1 reference

1 August 2017

1 reference